Healthcare Corp of America (SWCAU) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	8-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'Healthcare Corp of America	'
Entity Central Index Key	'0001514682	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'SWCA	'
Entity Common Stock, Shares Outstanding	'	8,907,692
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$1,527,073	$2,614,375
Accounts receivable	1,322,165	1,512,254
Inventory	427,660	638,858
Rebates receivable	1,780,546	2,072,049
Prepaid expenses and other current assets	77,117	164,450
Total current assets	5,134,561	7,001,986
Property and equipment, net	1,071,859	1,148,515
Deferred financing costs, net	246,086	254,252
Software, net	374,993	399,383
Other assets	362,566	406,463
Total assets	7,190,065	9,210,599
Current liabilities:	'	'
Accounts payable	5,250,349	5,184,273
Accrued expenses	3,896,012	3,294,467
Deferred revenue	1,766,375	2,090,614
Senior convertible note, net of debt discount	2,066,463	1,296,776
Junior convertible note, net of debt discount	74,591	0
Current portion of capital leases	209,267	216,400
Other current liabilities	12,125	19,503
Total current liabilities	13,275,182	12,102,033
Incentive Notes	3,133,213	2,934,297
Capital leases, net of current portion	535,704	579,390
Derivative liabilities	4,703,589	5,405,889
Other liabilities	47,785	44,631
Total liabilities	21,695,473	21,066,240
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Common stock, $.0001 par value; 30,000,000 shares authorized; 8,907,492 and 8,832,492 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	890	882
Additional paid-in capital	23,724,108	23,327,727
Accumulated deficit	-38,230,406	-35,184,250
Total stockholders' deficit	-14,505,408	-11,855,641
Total liabilities, redeemable securities and stockholders' deficit	$7,190,065	$9,210,599

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2014	Dec. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	8,907,492	8,832,492
Common stock, shares outstanding	8,907,492	8,832,492

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Sales	$14,921,025	$11,961,723
Cost of sales	14,302,185	11,450,011
Gross profit	618,840	511,712
Operating expenses:	'	'
Selling, general and administrative	3,483,049	2,974,020
Loss from operations	-2,864,209	-2,462,308
Other income (expense):	'	'
Interest expense	-884,247	-1,186,305
Change in fair value of derivative liabilities	702,300	0
Total other income (expense)	-181,947	-1,186,305
Loss before provision for income taxes	-3,046,156	-3,648,613
Provision for income taxes	0	0
Net loss	($3,046,156)	($3,648,613)
Earnings per share:	'	'
Basic and diluted loss per share (in dollars per share)	($0.34)	($0.09)
Weighted average number of shares outstanding (in shares)	8,846,103	40,250,009

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2013	($11,855,641)	$882	$23,327,727	($35,184,250)
Balance (in shares) at Dec. 31, 2013	'	8,832,492	'	'
Issuance of shares of common stock in connection with settlement of disputes	112,500	8	112,492	'
Issuance of shares of common stock in connection with settlement of disputes (in shares)	'	75,000	'	'
Stock based compensation	283,889	'	283,889	'
Net loss	-3,046,156	0	0	-3,046,156
Balance at Mar. 31, 2014	($14,505,408)	$890	$23,724,108	($38,230,406)
Balance (in shares) at Mar. 31, 2014	'	8,907,492	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Cash used in operating activities:	'	'	'
Net loss	($3,046,156)	($3,648,613)	$24,544,708
Adjustments to reconcile net loss to cash used in operating activities:	'	'	'
Depreciation and amortization	112,666	74,693	'
Non cash interest expense	815,188	218,566	'
Stock-based compensation	283,889	480,000	'
Note-based compensation	18,394	0	'
Mark to market adjustment on derivative liabilities	-702,300	0	'
Changes in assets and liabilities:	'	'	'
Accounts receivable	190,089	-857,974	'
Rebates receivable	291,503	-221,432	'
Inventory	211,198	119,693	'
Prepaid expenses and other current assets	112,836	1,055	'
Accounts payable and accrued expenses	539,188	1,730,261	'
Deferred revenues	-324,239	166,475	'
Other liabilities	-4,224	-1,415	'
Total cash used in operating activities	-1,501,968	-1,938,691	'
Cash used in investing activities:	'	'	'
Purchase of property and equipment	-11,620	-123,939	'
Total cash used in investing activities	-11,620	-123,939	'
Cash from financing activities:	'	'	'
Proceeds from senior convertible note	500,000	0	'
Proceeds from notes payable	0	611,311	'
Debt costs	-22,895	0	'
Warrants issued	0	120,937	'
Payments of capital leases	-50,819	-51,729	'
Total cash provided by financing activities	426,286	680,519	'
Net increase (decrease) in cash	-1,087,302	-1,382,111	'
Cash, beginning of period	2,614,375	1,791,134	1,791,134
Cash, end of period	1,527,073	409,023	2,614,375
Supplemental disclosures:	'	'	'
Interest	-69,059	-960,416	'
Income taxes	0	0	'
Issuance of shares in settlement of disputes	($112,500)	$0	'

Description_of_Business

Description of Business	3 Months Ended
	Mar. 31, 2014
Description Of Organization and Business Operations [Abstract]	'
Description of Organization and Business Operations Disclosure [Text Block]	'
	1. Description of Business
	Selway Capital Acquisition Corporation (“SCAC” or “Selway”) was originally incorporated under the laws of Delaware on January 12, 2011 for the purpose of acquiring one or more operating businesses through merger or capital stock exchange. On January 25, 2013, an agreement and plan of merger (the “Merger”) was entered into between SCAC and Healthcare Corporation of America (“HCCA”). The Merger closed on April 10, 2013 with SCAC being the surviving entity upon the consummation of the Merger (see Note 3).
	HCCA and its wholly-owned subsidiaries, Prescription Corporation of America Benefits (“PCA Benefits”) and Prescription Corporation of America (“PCA”), are engaged in providing benefits management and mail order pharmaceutical fulfillment services to companies primarily in the northeast United States.
	On June 3, 2013, SCAC amended its articles of incorporation to change its name to Healthcare Corporation of America (collectively with its subsidiaries, the “Company”).
	On April 22, 2013, the Company’s board of directors approved the change of its fiscal year end from December 31 to June 30.
	On November 7, 2013, the board of directors approved the change of its fiscal year end back to December 31.
	The accompanying historical consolidated financial statements represent the financial position and results of operations of HCCA through April 10, 2013 and the financial position and results of operations of the Company thereafter (see Note 3).

Liquidity_and_Financial_Condit

Liquidity and Financial Condition	3 Months Ended
	Mar. 31, 2014
Liquidity and Financial Condition [Abstract]	'
Liquidity and Financial Condition Text block [Text Block]	'
	2. Liquidity and Financial Condition
	The Company has a working capital deficit and a history of recurring losses and negative cash flows from operating activities. As of March 31, 2014 and December 31, 2013, the Company has working capital deficiencies of $8,140,621 and $5,100,047, respectively and stockholders’ deficit of $14,505,408 and $11,855,641, respectively. During the three months ended March 31, 2014 and the year ended December 31, 2013, the Company incurred net losses of $3,046,156 and $24,544,708, respectively, and negative cash flows from operating activities of $1,501,968 and $9,606,056, respectively. Collectively, these factors raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company is currently making efforts to raise capital in the form of debt and/or equity. No assurance can be given that the debt and/or equity can be raised and if available it will be on terms acceptable to the Company.
	The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

The_Merger

The Merger	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Merger Disclosure [Text Block]	'
	3. The Merger
	On January 25, 2013, an Agreement and Plan of Merger (the “Agreement”) was entered into by and among the Company, Selway Merger Sub, Inc., a New Jersey corporation and wholly owned subsidiary of the Company (“Merger Sub”), HCCA, PCA, and representatives of HCCA and the Company. On April 10, 2013 (the “Closing Date”), the Merger and other transactions contemplated by the Agreement closed.
	Pursuant to the Agreement, Merger Sub merged with and into HCCA, resulting in HCCA becoming a wholly owned subsidiary of the Company. PCA and PCA Benefits, a dormant entity, remain wholly owned subsidiaries of HCCA.
	Holders of all of the issued and outstanding shares of common stock of HCCA immediately prior to the time of the Merger had each of their shares of common stock of HCCA converted into the right to receive: (i) a proportional amount of 5,200,000 shares of the Company’s Series C common stock and promissory notes with an aggregate face value of $7,500,000 (collectively, the “Closing Payment”); plus (ii) a proportional amount of up to 2,800,000 shares of the Company’s common stock, if any, (the “Earn-out Payment Shares”) issuable upon the Company achieving certain consolidated gross revenue thresholds as more fully described below; plus (iii) the right to receive a proportional amount of the proceeds from the exercise of certain warrants being issued to Selway Capital Holdings, LLC, Selway’s sponsor, as more fully described below. A portion of the Closing Payment (520,000 shares and promissory notes with an aggregate face value of $750,000) was being held in escrow for a period of 12 months following the Merger to satisfy indemnification obligations of HCCA. Effective December 20, 2013, the escrowed portion of the Closing Payment, together with a portion of the shares issued to HCCA’s investment banking advisor (an aggregate of 546,002 shares, and promissory notes with an aggregate face value of $750,000) were released from escrow and cancelled.
	The promissory notes included in the Closing Payment are non-interest bearing and subordinated to all senior debt of the combined company in the event of a default under such senior debt. The notes will be repaid from 18.5% of the Company’s free cash-flow (as defined) in excess of $2,000,000. The Company will be obligated to repay such notes if, among other events, there is a transaction that results in a change of control of the Company. The Company valued the notes at $1,977,570, which represented the present value of the estimated future cash flows to be generated by the combined companies discounted using an interest rate reflective of the uncertainty and credit risk of the notes.
	Certain members of HCCA’s management received an aggregate of 1,500,000 shares of our common stock (the “Management Incentive Shares”), which shares were placed in escrow and subject to release in three installments through June 30, 2015. Subsequently, certain members of HCCA management agreed to cancel an aggregate of 750,000 shares pursuant to rescission agreements entered into June 2013. Of the remaining Management Incentive Shares outstanding, 400,000 shares have vested but remain in escrow until June 30, 2014 and 350,000 shares will vest on June 30, 2015 and will remain in escrow until June 30, 2015.
	As part of the Merger, Selway’s net liabilities, consisting primarily of warrant liabilities, were assumed. As part of its Initial Public Offering, Selway issued 2,000,000 warrants, with an exercise price of $7.50 and an expiration date of November 6, 2016 (“Selway IPO Warrants”). These warrants are classified as liabilities based on certain anti-dilution features. The Selway IPO Warrants were recorded at $4,018,000 based on the closing price of the warrants on the date of Merger.
	The Earn-out Payment Shares, if any, will be issued as follows: (i) 1,400,000 shares if the Company achieves consolidated gross revenue of $150,000,000 for the twelve months ended March 31, 2014 or June 30, 2014; and (ii) 1,400,000 shares if the Company achieves consolidated gross revenue of $300,000,000 for the twelve months ended March 31, 2015 or June 30, 2015. In the event the Company does not achieve the first earn-out threshold, but does achieve the second earn-out threshold, then all of the Earn-out Payment Shares shall be issued. If the Company consolidates, merges or transfers substantially all of its assets prior to June 30, 2015 at a valuation of at least $15.00 per share, then all of the Earn-out Payment Shares not previously paid out shall be issued immediately prior to such transaction. If, prior to achieving either earn-out threshold the Company acquires another business in exchange for its equity or debt securities, then any remaining earn-out thresholds may be adjusted by the independent members of the Company’s board of directors at their sole discretion. The Company estimates that it will not achieve any of the abovementioned revenue targets and, therefore, no provision has been made for the Earn-out Payment Shares.
	The Agreement required 10% of the consideration, or 520,000 shares of the Company’s Series C common stock and promissory notes with a face value of $750,000 to be held in escrow for a period of one year. As a result of the investigation and subsequent restatement (see Note 4), in December 2013 these shares of stock and promissory notes were returned to the Company. Also in December 2013, the rights to additional proceeds from the exercise of certain warrants issued to Selway Capital Holdings, LLC as part of the merger were cancelled.
	In connection with a bridge financing (the “Bridge Financing”) completed by HCCA in September 2012, HCCA issued 59.25 units, each unit consisted of 10,000 Convertible Preferred Shares, a warrant for 5,000 shares of common stock that, upon a merger with Selway, converted to warrants with the same terms as Selway IPO warrants and a Promissory Note with a face value of $100,000 (“Promissory Notes”). At the time of the Merger, holders of all of the issued and outstanding shares of preferred stock of HCCA, by virtue of the Merger, had each of their shares of Preferred Stock of HCCA converted into the right to receive a proportional amount of 592,500 shares of the Company’s Series C common stock and warrants to purchase 296,250 shares of the Company’s Series C common stock. If a Merger with Selway or equivalent, as defined in the Preferred Stockholder agreement, occurred before the maturity date of the promissory notes, the preferred stock converted on a 1 to 1 basis into Series C Common Stock of Selway. If such Merger did not occur, then at the maturity of the Promissory Notes, the Preferred Stock converted into 3.7% of common stock of HCCA on a fully diluted basis. Upon issuing the preferred stock, HCCA determined the contingent beneficial conversion feature to the holders of the Preferred Stock if the Merger with Selway occurred to be $3,532,858 and recorded that as a deemed dividend to the Preferred Stockholders upon the closing of the Merger.
	The warrants issued in connection with the bridge loan were initially exercisable at $7.50 into shares of common stock of HCCA and expired on November 7, 2016. The warrants contained certain anti-dilution that caused them to be classified as liabilities. Upon completion of the Merger with Selway, the warrants became exercisable in Series C shares of Common Stock of Selway. The exercise price and expiration date remained the same.
	The Promissory Notes bore interest at 8%, were convertible into 10,000 shares of Series C Common Stock if a transaction with Selway occurred and matured on the earlier of a transaction with Selway or September 12, 2013. HCCA allocated the value received from the sale of the units first to the estimated fair value of warrants. The residual value was then allocated to the preferred stock and promissory note based on their relative fair values. As a result of the allocation, HCCA recorded a debt discount of $2,445,242. The debt discount was amortized to interest expense over the term of the Promissory Note. HCCA recorded interest expense of $1,732,047, including $1,018,851 to recognize the unamortized debt discount at the April 10, 2013 transaction date. HCCA recorded interest expense of $713,196 related amortization of the debt discount in the year ended December 31, 2012. Upon issuing the promissory notes, HCCA determined the contingent beneficial conversion feature to the holders of the Promissory Notes, if they converted into shares of Selway and recorded additionally $1,182,327, as additional interest expense upon the conversion of the promissory notes. In accordance with the terms of the promissory notes issued in the Bridge Financing, at the time of the Merger, notes in the aggregate amount of $3,159,624 (including principal and interest accrued to date) were converted into 315,959 shares of the Company’s Series C common stock and notes in the aggregate principal amount of $3,025,000 were repaid in full. The promissory note included in the Bridge Financing was only convertible into shares of common stock if the transaction with Selway closed before the maturity of the note. At the issuance of the Bridge Financing, the Company determined that a contingent beneficial conversion feature existed representing the difference in the value of the underlying shares and the allocated value to the promissory note. Upon closing of the transaction, the Company recognized the contingent beneficial conversion feature in additional paid-in capital and recorded $1,182,327 as additional interest expense.
	In connection with the Bridge Financing, HCCA executed a registration rights agreement that required it to register the shares underlying the Bridge Financing if the transaction was completed. The agreement required HCCA to file a registration statement within 60 days of the completion of the transaction with Selway and have the registration statement declared effective within 120 days. The agreement requires damages of 1% per month of the Bridge Financing, capped at 10%, for each month the Company does not comply with the requirement. As a result of the restatements and investigation, the Company did not file a registration statement and have it declared effective within the period required and recorded the maximum damages under the agreement ($592,000).
	In conjunction with the merger of Merger Sub into HCCA:
		·	The Company entered into exchange agreements with three beneficial holders of HCCA’s bridge loan who were also beneficial holders of greater than 5% of the Company’s Series A common stock. Pursuant to the exchange agreements, such holders converted an aggregate of 281,554 shares of the Company’s Series A common stock to the Company’s Series C common stock. In conjunction with the exchange, such holders were repaid bridge notes in the aggregate principal amount of $3,025,000.
		·	The Company entered into exchange agreements with three beneficial holders of greater than 5% of the Company’s Series A common stock. Pursuant to the exchange agreements, such holders converted an aggregate of 878,481 shares of the Company’s Series A common stock to the Company’s Series C common stock and received $3.53 per share of Series A common stock exchanged, or an aggregate of $3,101,038.
		·	An aggregate of $11,948,361 was released from the Company’s trust account, reflecting the number of shares of the Company’s Series A common stock that were converted into the Company’s Series C common stock, of which $237,007 was paid to the underwriters from the Company’s initial public offering. The Company incurred other costs related to the transaction totaling $577,069 and recorded both these costs and the costs paid to the underwriters as a reduction to Additional Paid In Capital.
		·	The placement warrants held by the Company’s founders were converted into the right to receive: (i) an aggregate of 100,000 shares of common stock; and (ii) warrants to purchase an aggregate of 1,000,000 shares of common stock at an exercise price of $10.00 per share. The proceeds from the exercise of the exchange warrants will be paid: (i) 75% to the holders of all of the issued and outstanding shares of common stock of HCCA immediately prior to the time of the merger; and (ii) 25% to certain members of HCCA management. The exchange warrants are only exercisable for cash, may not be exercised on a cashless basis, and must be exercised if the closing price for the combined company’s common stock exceeds $12.00 per share for 20 trading days in any 30-trading-day period. On November 22, 2013, the Company cancelled these warrants and issued a new warrant to purchase 1 million shares of common stock. The replacement warrant was recorded to additional paid in capital. Per the terms of the warrant agreement, the warrant’s initial exercise price was $7.50 per share, subject to adjustment upon the first subsequent financing of the Company. This financing occurred on December 31, 2013 upon which the exercise price of this warrant was adjusted from $7.50 to $1.50. The new warrants do not include the provision to share the exercise proceeds with former shareholders of HCCA or management. The Company recorded a charge to interest expense of $561,712 reflecting the value of the modification to the warrant.
	Pursuant to an engagement letter entered into by HCCA with its investment banking adviser, 5% of all consideration received was owed to the adviser. Accordingly the Company issued 335,000 shares of common stock representing 5% of the common stock and incentive stock, as adjusted, received by HCCA and issued an incentive note of $500,000 representing 5% of the incentive notes issued to HCCA. The present value of the incentive note was recorded to additional paid in capital and is included in liabilities assumed. 26,002 shares issued to the advisor were placed in escrow and cancelled in December 2013.
	The business combination of the Company and HCCA was accounted for as a reverse recapitalization of HCCA, since prior to the merger the Company was a shell corporation as defined under Rule 12b-2 of the Exchange Act. HCCA was treated as the accounting acquirer in this transaction due to the following factors:
		1)	HCCA’s management pre-closing remained as the management of the Company post-closing;
		2)	The members of the board of directors of HCCA pre-closing represent the majority of directors of the Company post- closing; and
		3)	The majority of shares of the Company post-closing were still owned by HCCA shareholders, who represented 60% of the Company’s shares outstanding immediately after closing, if all shares subject to conversion in our post-closing tender offer actually convert to Series C (non-redeemable) common shares, and 65% of the Company’s shares outstanding if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer. Estimates of HCCA’s ownership do not include shares underlying warrants held by public investors and the Company’s sponsors restricted incentive shares held by management. However, HCCA shareholders would still have 51% of the Company’s shares post-closing when including shares underlying warrants and restricted shares and assuming all redeemable shares convert to Series C shares, and 54% of the Company’s shares post-closing if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	4. Significant Accounting Policies
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements including disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results could differ from these estimates.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
	Accounts Receivable
	Accounts receivable represent amounts owed to the Company for products sold and services rendered net of an allowance for doubtful accounts. The Company grants unsecured credit to its customers. The Company continuously monitors the payment performance of its customers to ensure collections and minimize losses. Management does not believe that significant credit risks exist. An allowance for doubtful accounts is based upon the credit profiles of specific customers, economic and industry trends and historic payment experience. There is no allowance for doubtful accounts at March 31, 2014 and December 31, 2013.
	Inventory
	Inventories consist of finished pharmaceutical products and are recorded at the lower of cost or market, with the cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in values is first recognized.
	Rebates
	Pharmaceutical manufacturers offer rebates for selected brand drugs. The Company currently receives these rebates through a third party administrator. The rebates are considered earned when members (employees of customers) order the drugs. Rebates earned are paid to the Company by the third party administrator quarterly. Rebates earned are recognized as a reduction to cost of revenue. The portion of the rebate payable to customers is simultaneously recognized as a reduction of revenue. Management evaluates rebates receivable at the end of every reporting period and adjusts the amount reflected on the accompanying balance sheet to net realizable value. An adjustment is also made to the rebate payable to customers to correspond with any adjustment that applies to rebates receivable.
	Property and Equipment
	Property and equipment are stated at cost less accumulated amortization and depreciation. Leasehold improvements are amortized using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the assets. Furniture and fixtures are depreciated using the straight-line method over the estimated useful lives of the assets of 5 years. Computer equipment and software are depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 5 years.
	Internal-Use Software Development Costs
	The Company capitalizes certain costs associated with the purchase and/or development of internal-use software, including its website. Generally, external and internal costs incurred during the application development stage of a project are capitalized. The application development stage of a project generally includes software design and configuration, coding, testing and installation activities. Training and maintenance costs are expensed as incurred. Upgrades and enhancements are capitalized if it is probable that such expenditures will result in additional functionality. Capitalized software costs are amortized using the straight-line method over the estimated useful life of the assets, which approximates 3 years.
	Long-Lived Assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the fair value of the asset as compared to its carrying value. During the three months ended March 31, 2014 and March 31, 2013, the Company did not record any impairment charges.
	Investments Held in Trust
	The Company applies the provisions of ASC Topic 320-10, Investment - Debt and Equity, to account for investments held in trust, which comprise only of held-to maturity securities. Held-to-maturity securities are those securities, which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost on the accompanying balance sheets and adjusted for any amortization or accretion of premiums or discounts.
	Deferred Financing Costs
	Costs related to obtaining long-term debt financing have been capitalized and amortized over the term of the related debt using the straight line method. Amortization of deferred financing costs charged to interest expense was $31,061 and $400,704 for the three months ended March 31, 2014 and 2013, respectively. The unamortized balance was $246,086 and $254,252 at March 31, 2014 and December 31, 2013, respectively.
	Derivative Financial Instruments
	The Company applies the provisions of ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC Topic 815-40”), under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, such warrants are recorded as a liability and are revalued at fair value at the end of each reporting period. Furthermore, under derivative accounting, the warrants are initially recorded at their fair value. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as a change in fair value in the statement of operations on the issuance date.
	Debt Discounts
	Debt discounts are amortized using the effective interest rate method over the term of the related debt. The result achieved using the straight-line method is not materially different than those which would result using the effective interest method.
	Share-Based Payments
	Share-based payments to employees are measured at the fair value of the award on the date of grant based on the estimated number of awards that are ultimately expected to vest. The compensation expense resulting from such awards is recorded over the vesting period of the award in selling, general and administrative expenses on the accompanying consolidated statements of operations.
	Share-based payments to non-employees for services rendered are recorded at either the fair value of the services rendered, or the fair value of the awards, whichever is more readily determinable. The expense resulting from such awards is marked to market over the vesting period of the award in selling, general and administration expenses on the accompanying consolidated statements of operations.
	Revenue Recognition
	The Company typically enters into annual renewable agreements with its customers to provide pharmacy benefit management on a fixed price or self-insured basis. The Company records revenues from all its current contracts with customers gross as the Company acts as principal based on the following factors: 1) the Company has a separate contractual relationship with its customers and with its claims adjudicator to whom the Company pays the costs of the prescription drugs consumed by its customers (the claims), 2) the Company through its claim adjudicator is responsible to validate and manage the claims, and 3) the Company bears the credit risk for the amount due from the customers. Revenues are recorded monthly as earned. The Company also operates a mail order pharmacy that services plan members. All revenues and associated costs from dispensing drugs by the mail order pharmacy to our plan members, excluding the members’ co-pay are eliminated as inter-company revenues. Some of the contracts contain terms whereby the Company makes certain financial guarantees regarding prescription costs. Actual performance is compared to the guaranteed measure throughout the period and accruals are recorded as an offset to revenue if the Company fails to meet a financial guarantee.
	Cost of Sales
	Cost of sales includes claim payments for both fixed- price and self-insured programs, administrative fees paid for processing the claims to the claims adjudicator and, the cost of prescription drugs of the mail order pharmacy.
	Advertising Expenses
	Advertising expenses are expensed as incurred and included in selling, general and administrative expenses on the accompanying statements of operations. Advertising expenses were approximately $0 and $24,624 for the three months ended March 31, 2014 and 2013, respectively.
	Income Taxes
	The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established when realization of net deferred tax assets is not considered more likely than not.
	Uncertain income tax positions are determined based upon the likelihood of the positions being sustained upon examination by taxing authorities. The benefit of a tax position is recognized in the consolidated financial statements in the period during which management believes it is more likely than not that the position will not be sustained. Income tax positions taken are not offset or aggregated with other positions. Income tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of income tax benefit that is more than 50 percent likely of being realized if challenged by the applicable taxing authority. The portion of the benefits associated with income tax positions taken that exceeds the amount measured is reflected as income taxes payable.
	The Company recognizes interest related to uncertain tax positions in interest expense. The Company recognizes penalties related to uncertain tax positions in income tax expense.
	Fair Value Measurements
	The Company applies recurring fair value measurements to its derivative instruments in accordance with ASC 820, Fair Value Measurements. In determining fair value, the Company uses a market approach and incorporates assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation techniques. These inputs can be readily observable, market corroborated or generally unobservable internally-developed inputs. Based upon the observability of the inputs used in these valuation techniques, the Company’s derivative instruments are classified as follows:
	Level 1:	The fair value of derivative instruments classified as Level 1 is determined by unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
	Level 2:	The fair value of derivative instruments classified as Level 2 is determined by quoted market prices for similar assets or liabilities in active markets, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
	Level 3:	The fair value of derivative instruments classified as Level 3 is determined by internally-developed models and methodologies utilizing significant inputs that are generally less readily observable from objective sources.
	At March 31, 2014 and December 31, 2013 the Company had 2,000,000 warrants exercisable into its shares of common stock that were issued in connection with Selway’s initial public offering (“Selway IPO Warrants”). These warrants are publicly traded and are classified as liabilities. Additionally, HCCA issued 296,250 warrants in connection with the Bridge Financing with identical terms as the Selway IPO Warrants. The Company has valued all of these warrants at March 31, 2014 and December 31, 2013 based on the closing price of the Selway IPO Warrants. Because the market for the Selway IPO Warrants is not active, the valuation is classified as a Level 2 measurement. These warrants are exercisable at $7.50 a share and expire on November 7, 2016.
	On December 31, 2013, the Company executed a forbearance agreement with the holders of its senior convertible debt. Among other things, this agreement required the Company to issue 425,000 shares of common stock to the senior convertible debt holders and permit the redemption of 25,000 shares at the rate of $10 per share through June 30, 2019 (the “Senior Debt Redemption Feature”). The Company evaluated the redemption terms embedded in the agreement and determined that such terms should be bifurcated from the common stock and recorded as a liability. The Company determined the fair value of the Senior Debt Redemption Feature utilizing a Black-Scholes valuation model. The key inputs to the valuation were the Company’s share price at the date of valuation and the expected volatility. The Company did not become publicly traded until April 11, 2013 and therefore determined its expected volatility from a selection of similar publicly traded companies. The valuation is classified as a Level 2 valuation based on the use of volatility calculations from other publicly traded companies.
	On December 31, 2013, the Company issued $2,325,125 of Junior Convertible Notes convertible into 1,550,083 shares of common stock maturing on December 31, 2015 and Warrants to acquire 1,550,083 shares of common stock at $1.50 that expire on December 31, 2018. The conversion feature in the Junior Convertible Notes and Warrant agreement contain anti-dilution provisions that cause the related conversion rate and exercise price to decrease and the related shares increase if the Company is deemed to issue equity at a per share value less than the then conversion rate and exercise price. The Company evaluated this feature and determined that conversion feature in the Junior Convertible Notes should be bifurcated from the underlying debt agreement and recorded as a liability and the Warrants to be classified as liabilities (the Junior Convertible Notes Conversion Feature and Warrants).
	The Company utilized a Monte Carlo simulation model to estimate the value of the Junior Convertible Notes Conversion Feature and Warrants. The Company classified this valuation as Level 3 valuation as the key inputs to the Monte Carlo include timing of equity raises and the estimated share price at such dates.
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of March 31, 2014:
			Level 1		Level 2		Level 3		Total
	Senior debt redemption feature		$	-	$	250,000	$	-	$	250,000
	Warrants and convertible feature junior convertible note		$	-	$		$	4,201,000	$	4,201,000
	Warrants		$	-	$	252,589	$	-	$	252,589
	Total derivative liabilities		$	-	$	502,589	$	4,201,000	$	4,703,589
	The table below presents the activity in the Company’s derivative instruments measured at fair value on a recurring basis for the three months ended March 31, 2014:
			Beginning of		Issuances		Changes in		Balance at
			Period				Fair Value		end of Period
	Warrants and convertible feature convertible notes		$	5,087,000	$	-	$	-886,000	$	4,201,000
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of December 31, 2013:
			Level 1		Level 2		Level 3		Total
	Senior debt redemption feature		$	-	$	250,000	$	-	$	250,000
	Warrants and convertible feature junior convertible note		$	-	$		$	5,087,000	$	5,087,000
Warrants		$	-	$	68,889	$	-	$	68,889
Total derivative liabilities		$	-	$	318,889	$	5,087,000	$	5,405,889
Fair Value of Financial Instruments
The fair values of cash and cash equivalents, accounts receivable, rebates receivable and accounts payable approximate their carrying values due to the short-term nature of the instruments. The fair values of long-term debt approximates their carrying value due to the fact that these instruments were modified or executed at year-end. The fair value of investments held in trust is not materially different than its carrying value because of the short-term nature of the investments.
Risks and Concentrations
The Company utilizes the services of a single claims adjudicator. If there is an adverse situation in this relationship, the Company’s mail order pharmaceutical fulfillment services would be ineffective until a replacement claims adjudicator was obtained.
Approximately 25% of the Company’s revenues for the three months ended March 31, 2014 were derived from one customer. Revenues from this customer were 13% of the Company’s revenues for the year ended December 31, 2013. No amounts were due from this customer at March 31, 2014 or December 31, 2013. In addition, the customers of one of the Company’s resellers accounted for approximately 25% of the Company’s revenue for the three months ended March 31, 2014 and for the year ended December 31, 2013. Amounts due from these customers represented 63% and 76% of accounts receivable at March 31, 2014 and December 31, 2013, respectively.
Cash and Cash Equivalents
The Company considers all cash in bank, money market funds and certificates of deposit with an original maturity of less than three months to be cash equivalents. The Company maintains its cash and cash equivalents in one financial institution. Cash balances on hand at this financial institution may exceed the insurance coverage provided to the Company by the Federal Deposit Insurance Corporation at various times during the year.
Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share are determined in the same manner as basic earnings (loss) per share, except that the number of shares is increased to include potentially dilutive securities using the treasury stock method. Because the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share because the effect of including them is anti-dilutive.
		Three Months		Three Months
		Ended March		Ended March
		31, 2014		31, 2013
Basic and Diluted:
Net loss		$	-3,046,156	$	-3,648,613
Weighted average shares			8,846,103		40,250,009
Basic loss per common share		$	-0.34	$	-0.09
The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
			Three Months		Three Months
			Ended March		Ended March
			31, 2014		31, 2013
Dilutive Potential Common Shares
Warrants			5,596,106		1,585,833
Restricted stock awards			-		75,292
Convertible notes payable			3,750,083		2,666,667

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	5. Property and Equipment
	Property and equipment is as follows:
		March 31,		December 31,
		2014		2013
	Furniture, fixtures and equipment	$	1,662,201	$	1,662,201
	Leasehold improvements		60,168		50,548
			1,722,369		1,712,749
	Accumulated depreciation and amortization		-650,510		-564,234
	Net property and equipment	$	1,071,859	$	1,148,515
	Amortization and depreciation was approximately $88,276 and $74,693 for the three months ended March 31, 2014 and 2013, respectively.

Software_net

Software, net	3 Months Ended
	Mar. 31, 2014
Capitalized Computer Software, Net [Abstract]	'
Research, Development, and Computer Software Disclosure [Text Block]	'
	6. Software, net
	Software, net is as follows:
		March 31,		December 31,
		2014		2013
	Software costs	$	472,489	$	472,489
	Accumulated amortization		-97,496		-73,106
	Net software costs	$	374,993	$	399,383
	Amortization expense was $24,390 and $0 for the three months ended March 31, 2014, and 2013 respectively.

Investments_Held_in_Trust

Investments Held in Trust	3 Months Ended
	Mar. 31, 2014
Investment Held In Trust [Abstract]	'
Investment [Text Block]	'
	7. Investments Held in Trust
	Following the initial public offering (“IPO”) of Selway in November 2011, a total of $20.6 million was placed in a trust account maintained by American Stock Transfer & Trust Company, as trustee. None of the funds held in the trust were to be released from the trust account, other than interest income, net of taxes, until the earlier of (i) consummation of an acquisition and (ii) redemption of 100% of the public shares sold in the IPO if Selway failed to consummate an acquisition by May 14, 2013.
	On April 10, 2013, Selway closed the acquisition of HCCA through the Merger (see Notes 1 and 3). At the time of the Merger, holders of 1,160,035 shares of redeemable common stock decided not to redeem their shares and accordingly approximately $11,948,000 was released from the escrow. As per the certificate of incorporation of Selway, the remaining balance of the trust account of approximately $8,652,000 was used to redeem the remaining 839,965 redeemable common shares through a tender offer which closed on August 15, 2013. The amount in trust can be invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940 having a maturity of 180 days or less. Prior to being released from the escrow, the United States government securities were in an account at Wells Fargo Bank, while the cash amount was in a JP Morgan Chase cash account. The United States government securities matured and the total trust balance of $8,652,482 was in cash.
	The Company classified its United States Treasury and equivalent securities as held-to-maturity in accordance with FASB ASC 320, “Investments - Debt and Equity Securities.” Held-to-maturity treasury securities are recorded at amortized cost on the accompanying balance sheet and adjusted for the amortization or accretion of premiums or discounts.

Deferred_Financing_Costs

Deferred Financing Costs	3 Months Ended
	Mar. 31, 2014
Deferred Finance Costs [Abstract]	'
Deferred Financing Cost [Text Block]	'
	8. Deferred Financing Costs
	Deferred financing costs are as follows:
	Balance January 1, 2014	$	254,252
	Costs incurred for forbearance, waiver and modification to the senior convertible note for the three months ended March 31, 2014		22,895
	Amortization for the three months ended March 31, 2014		-31,061
	Balance March 31, 2014	$	246,086

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	9. Accrued Expenses
	Accrued expenses are as follows:
			March 31,		December 31,
			2014		2013
	Accrued severance costs*		$	271,154	$	750,000
	Accrued rebates			691,983		596,905
	Accrued registration rights penalties**			910,000		864,000
	Accrued professional fees			480,000		67,686
	Accrued commissions			723,332		225,125
	Accrued franchise tax			303,981		263,981
	Accrued payroll			285,022		327,357
	Accrued expenses other			230,540		199,363
			$	3,896,012	$	3,294,467
		*	Payable to a former executive of the Company.
		**	Estimated penalties relating to late registration of shares of common stock in connection with the bridge notes and senior convertible note.

Line_of_Credit

Line of Credit	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	10. Line of Credit
	On April 11, 2013, the wholly-owned subsidiaries of HCCA, entered into a credit and security agreement for a secured revolving credit facility with an initial aggregate credit limit of $5,000,000. The facility has a term of 3 years, through April 11, 2016, during which the loan proceeds are to be used solely for working capital. The facility was terminated in September 2013 due to the Company’s inability to meet certain financial covenants and all outstanding balances under the line were repaid, and the carrying value of the related financing costs of $538,637 were written off to interest expense.

Junior_Convertible_Note

Junior Convertible Note	3 Months Ended
	Mar. 31, 2014
Junior Convertible Note [Abstract]	'
Junior Convertible Note [Text Block]	'
	11. Junior Convertible Note
	On December 31, 2013, the Company entered into a securities purchase agreement with certain investors and an administrative and collateral agent representing the investors. Pursuant to the securities purchase agreement, the Company issued $2,112,500 of Junior Convertible Notes due on December 31, 2015, which are convertible into shares of the Company’s common stock at an initial fixed conversion price equal to $1.50 per share, and included the conversion of $250,000 of accrued legal costs.
	In connection with its services related to the Junior Convertible Notes as well as the forbearance, waiver and modification agreement of the Senior Convertible Note (see Note 12) the Company agreed to pay the agent a fee in the form of junior convertible notes and warrants and accordingly Junior Convertible Notes in the amount of $212,625 were issued to the agent.
	In connection with Junior Convertible Notes, the Company issued warrants to purchase an aggregate of 1,550,083 shares of common stock (including warrants to purchase 141,750 shares issued to the Agent for its fees), at an initial exercise price of $3.00 per share (the “Exercise Price”), at any time on or prior to December 31, 2018 (the “Warrants”). The Warrants may also be exercised on a cashless basis.
	The conversion price of the Junior Convertible Notes (initially $1.50) as well as the exercise price of the related warrants (initially $3) are subject to further down adjustments depending on the terms of subsequent capital raises.
	The Company also agreed to secure the payment of all obligations under the notes by granting and pledging a continuing security interest in all of the Company’s and its subsidiaries’ property now owned or at any time hereafter acquired by them. The Junior Convertible Notes are subordinated to the Senior Convertible Notes.
	At the time of the transaction, the Company recorded a derivative liability in the amount of $5,087,000, a loan discount of $2,325,000 and an interest charge of $2,762,000. In addition, the Company incurred loan costs amounting to $202,035.
	In addition, as of March 31 2014 the Company recorded an accrual of $46,000 and a corresponding interest charge reflecting the estimated penalty relating to late registration of the underlying shares of common stock.

Senior_Convertible_Note

Senior Convertible Note	3 Months Ended
	Mar. 31, 2014
Senior Convertible Note [Abstract]	'
Senior Convertible Note [Text Block]	'
	12. Senior Convertible Note
	On July 17, 2013, the Company entered into a loan and security agreement with Partners for Growth III, LP (“PFG”) for a one-time convertible secured loan of $5,000,000 with a maturity date of July 17, 2018. Pursuant to the terms of the Loan Agreement, the loan is convertible at $8 per share and interest on the PFG Loan is payable on a monthly basis at an annual rate of prime plus 5.25% per annum, subject to certain reductions if certain financial targets are met.
	If the Company fails to achieve certain revenue and earnings targets, PFG may elect to accelerate the repayment of the loan portion of the PFG Loan over the shorter of the 24-month period from the date of the election or the remaining term of the loan. Upon acceleration of repayment, the Company must make monthly payments of principal and interest, such that 60% of the outstanding principal is repaid in the first year and 40% is paid in the second year.
	The Loan Agreement contains certain financial covenants as well as customary negative covenants and events of default.
	As part of consideration for the PFG Loan, the Company issued to Lender and its designees warrants to purchase an aggregate of 220,000 shares of Series C common stock, for $7.50 per share, at any time on or prior to July 17, 2018 (the “PFG Warrants”).
	At the time of the transaction, the Company recorded a beneficial conversion feature in the amount $654,144, the warrants were recorded as equity warrants in the amount of $1,154,144 and the notes were recorded at a value of $3,191,711 reflecting a loan discount of $1,808,289. In addition, the Company incurred loan costs amounting to $328,712.
	In addition, as of December 31, 2013 the Company recorded an accrual of $272,000 and a corresponding interest charge reflecting the estimated penalty relating to the late registration of the underlying shares of common stock.
	On October 15, 2013, the Company received a notice of events of default from PFG.
	On December 31, 2013, the Company entered into a Forbearance, Waiver and Modification to the loan agreement. Pursuant to the terms of the modification PFG (i) lent an additional $500,000 to the Company (received on January 6, 2014), (ii) The conversion price of the promissory notes issued under the original loan agreement and the modification was reduced to $2.50 per share from $7.50 per share, (iii) PFG’s right to accelerate repayment of the loan if certain conditions were not met was eliminated, (iv) The Company agreed to pay $150,000 in fees, (v) Certain financial covenants were revised, (vi) The number of shares issuable upon exercise of warrants issued to PFG was increased from 220,000 to 555,000 and the exercise price of the warrants was reduced to $3.00 per share from $8.00 per share, (vii) The number of shares issuable under contingently exercisable warrants was increased from 625,000 shares to 2,200,000 and the exercise price reduced from $8.00 per share to $2.50 per share, (viii) The Company issued 425,000 shares of its common stock to PFG, and (ix) PFG has the option, until June 30, 2019, to require the Company to purchase from it, at PFG’s option, up to 25,000 shares (of the 425,000) of common stock for a purchase price of $250,000.
	The revised financial covenants of the Senior Convertible Note, beginning July 1, 2014, require the Company to maintain a specified ratio of cash and accounts receivable to the outstanding Senior Convertible Note. The Company is currently not in compliance with this covenant and needs additional equity investments to meet this requirement. There is no guarantee that such equity investments would be available to the Company in order to comply with this covenant, and accordingly the Senior Convertible Note is presented as current in the accompanying consolidated balance sheet.
	The Company recorded the Forbearance, Waiver and Modification to the loan agreement as an extinguishment of the July 2013 Senior Convertible Note. Accordingly as of December 31, 2013 the Company fully amortized the remaining balance of the debt costs incurred in connection with the original note in the amount of $298,129 and, wrote off the balance of the loan discount of $1,642,529 to loss on extinguishment. As of December 31, 2013 the Company recorded the new note at its estimated fair value of $1,296,776 which is net of the additional $500,000

Bridge_Notes

Bridge Notes	3 Months Ended
	Mar. 31, 2014
Disclosure Of Bridge Notes [Abstract]	'
Disclosure Of Bridge Notes [Text Block]	'
	13. Bridge Notes
	On September 12, 2012, the Company completed a bridge financing (the “Bridge Financing”) consisting of 59.25 units, each unit consisting of 10,000 preferred shares, 5,000 warrants and a promissory note with a face value of $100,000. At the time of the transaction, the value of the units was allocated as follows: Preferred Stock was recorded at a value of $2,362,517, the warrants were recorded as a warrant liability of $82,726 and the notes were recorded at a value of $3,479,757, reflecting a loan discount of $2,445,242. In addition, the Company incurred loan fees amounting to $673,229. The Company recorded interest expense associated with the amortization of the loan discount and the loan fees through the Merger date.
	At the time of the Merger, holders of all of the issued and outstanding shares of preferred stock of HCCA, by virtue of the Merger, had each of their shares of preferred stock of HCCA converted into the right to receive a proportional amount of 592,500 shares of the Company’s Series C common stock and warrants to purchase 296,250 shares of the Company’s Series C common stock. In accordance with the terms of the promissory notes issued in the Bridge Financing, at the time of the Merger, notes in the aggregate amount of $3,159,592 (including principal and interest accrued to date) were converted into 315,959 shares of the Company’s Series C common stock and notes in the aggregate principal amount of $3,025,000 were repaid in full.

LongTerm_Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2014
Long-term Debt and Capital Lease Obligations, Current [Abstract]	'
Long-term Debt [Text Block]	'
	14. Long-Term Debt
	Incentive Notes
	Upon consummation of the merger (see Note 3), Holders of all of the issued and outstanding shares of common stock of HCCA immediately prior to the time of the Merger had each of their shares of common stock of HCCA converted into the right to receive a proportional amount of 5,200,000 shares of the Company’s Series C common stock and promissory notes with an aggregate face value of $7,500,000 (collectively, the “Closing Payment”). On December 31, 2013, promissory notes with a face value of $750,000 were returned to the Company (see Note 3).
	In addition, the Company issued to its management $2,500,000 of Management Incentive Notes and paid fees in connection with the transaction by issuing promissory notes having an aggregate principal amount of $500,000, which reflects five percent of all promissory notes issued in the transaction.
	The above described notes with an aggregate face value of $10,500,000 have identical terms and conditions, are non-interest bearing and are subordinated to all senior debt of the Company in the event of a default under such senior debt. The notes will be repaid from 25% of the Company’s free cash-flow (defined as in the notes) in excess of $2,000,000. The Company will be obligated to repay such notes if, among other events, there is a transaction that results in a change of control of the Company. These notes are subordinated to all other debt, and repayment could be deferred if the terms of other debt instruments then outstanding prohibit repayment.
	The notes were recorded at their estimated present value, based on the estimated time of repayment discounted to the balance sheet date. The Company will continue to re-evaluate its estimates on a periodic basis and adjust the present value of the notes accordingly. Of the Management Incentive Notes, $222,477, net of discount vested immediately and $395,514 is being recognized as management incentive compensation over the estimated payment periods.
		March 31, 2014		December 31, 2013
	Shareholder notes	$	6,750,000	$	6,750,000
	Placement notes		500,000		500,000
	Management incentive notes		2,500,000		2,500,000
			9,750,000		9,750,000
	Less debt discount		-6,616,787		-6,815,703
		$	3,133,213	$	2,934,297
	Future maturities of the Incentive Notes based on the Company’s estimates which do not reflect any limitation of repayment that may exist due to the terms of other debt then outstanding are as follows:
	June 30,
	2014	$	-
	2015		-
	2016		399,000
	2017		1,789,000
	2018		3,622,000
	Thereafter		3,940,000
		$	9,750,000
	Capital Leases
	The Company has entered into capital lease agreements for equipment, which expire at various dates through November 2019. The assets capitalized under these leases and associated accumulated depreciation at March 31, 2014 and December 31, 2013 are as follows:
		March 31,		December 31,
		2014		2013
	Furniture and equipment	$	1,050,343	$	1,050,343
	Accumulated depreciation		-431,014		-370,780
		$	619,329	$	679,563
	Amortization of capital leases is included in depreciation expense.
	Minimum future lease payments under capital lease obligations as of March 31, 2014 are as follows:
	Year Ended March 31,
	2015	$	264,006
	2016		240,390
	2017		169,297
	2018		137,316
	2019		35,747
	Thereafter		23,831
	Total future minimum lease payments		870,587
	Less amount representing interest		-125,616
	Present value of net minimum lease payments		744,971
	Less current portion		-209,267
		$	535,704

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	15. Stockholders’ Equity
	The Company is authorized 30,000,000 shares of common stock, par value $.0001, which shares may, but are not required to, be designated as part of one of three series, callable Series A, callable Series B and Series C shares. The holders of all common shares shall possess all voting power and each share shall have one vote.
	Series A – Holders of shares of Series A Common Stock are entitled to cause the Corporation to redeem all or a portion of their shares in connection with an acquisition transaction. If the holders of Series A Common Stock do not elect to have their shares redeemed, then they will automatically be converted to Series B Common Stock. As of March 31, 2014 there are no outstanding Series A Common Stock.
	Series B – Holders of shares of Series B Common Stock have the same rights as Series A Common Stock, except Series B Common Stock cannot be issued until such time as all outstanding shares of Series A Common Stock are converted to Series B Common Stock. The holders of Series B Common Stock have the right to participate in a Post-Acquisition Tender Offer or Post-Acquisition Automatic Trust Liquidation. 839,965 shares of Series B common shares were redeemed from the trust account on August 15, 2013. As of March 31, 2014 there were no outstanding redeemable shares.
	Series C – Holders of shares of Series C Common Stock have the same rights as Series A Common Stock, except holders of Series C Common Stock are not entitled to (1) cause the Corporation to redeem all or a portion of such Series C Common Stock in connection with the Acquisition Transaction, (2) share ratably in the Trust Account or (3) participate in a Post-Acquisition Tender Offer or Post-Acquisition Automatic Trust Liquidation. As of March 31, 2014, there are 8,907,492 shares of Series C Common Stock outstanding.
	In August 2013 following the redemption of the 839,965 shares of the series B common stock, the Series A Common Stock, Series B Common Stock and Series C Common Stock were consolidated into one series of Common Stock. The consolidation was on a one-for-one basis of the outstanding shares of each series of common stock. Currently following the automatic consolidation, only one series of Common Stock is authorized, which will be referred to as “Common Stock.”
	On December 31, 2013, 546,002 shares of common stock were returned to the Company (see Note 3).
	Prior to the merger the Company’s operations were conducted under the HCCA corporate entity (see Note 1). HCCA had authorized 50,000,000 shares of common stock, no par value. Upon the merger, every 7.6923 HCCA shares of common stock were exchanged into 1 share of the Company’s common stock.
	During 2012, the Company issued 2,120,200 shares of common stock with a fair value range of $0.01 to $0.31. These shares are freely tradable.
	During 2012, the Company settled a suit with a shareholder to repurchase 500,000 shares of its common stock. These shares were recorded as a stock redemption for $100,000 and the shares were received in February 2013. In February 2013, these shares were issued to employees in recognition of service performed and an expense of $480,000 was recorded representing the estimate fair value of the shares issued.
	As part of the Merger, 750,000 restricted shares of stock were issued to certain members of management. The shares were valued at $7.30, the share price at the date of the merger. 400,000 shares vested immediately and the remaining vest through June 30, 2015. In the year ended December 31, 2013, the Company recorded an expense of $2,920,000 for the shares that vested on the date of the Merger and $851,667 for the shares that vest through June 30, 2015.
	During the three months ended March 31, 2014, the Company issued 75,000 shares of common stock as part of the settlement of two disputed claims. The Company recorded a gain of approximately $340,000 in Selling General and Administrative expenses as result of the difference in value of the executed settlement and the Company’s initial estimate.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	16. Commitments and Contingencies
	Operating Leases
	The Company has certain non-cancelable operating leases for facilities and equipment that expire over the next three years. Future minimum payments for non-cancelable operating leases are as follows as of March 31, 2014:
	Year ended March 31,
	2015	$	205,510
	2016		216,975
	2017		201,465
		$	623,950
	Rent expense for the three months ended March 31, 2014 and 2013 was $48,346 and $48,234, respectively.
	Employment Agreements
	As of March 31, 2014, the Company had entered into employment agreements with senior officers and other members of management. The agreements specify aggregate guaranteed annual salaries of $1.7 million for each year of employment and extended through May 2017. The agreements allowed the Company to terminate these individuals for cause and not for cause. Depending on the terms of the individual contract upon termination without cause the Company would either be required to continue to pay salary through the original term of the contract or pay severance, typically one year of salary.
	As of March 31, 2014, the Company entered into employment contracts or employment arrangement letters with certain members of management and directors that among other things committed the Company to issuing approximately 1.9 million stock options. The Company does not currently have a stock option plan and 650,000 of these stock options will be granted at the time the stock option plan is appropriately established.
	Litigation
	During 2012, the Company filed a lawsuit against its past adjudicator of claims for overcharges, over payment on claims, errors and misclassifications, and rebates owed from drug manufacturers claiming damages of over $5 million. Additionally, the Company has recorded an expense for the amount owed for claims payable. The adjudicator of claims filed a counterclaim for amounts it claims are owed to it by the Company.
	In August 2013, the Company settled the suit with the claims adjudicator. Under the terms of the settlement the Company agreed to pay the claims adjudicator $2.7 million over 15 months commencing in September 2013. The settlement was discounted to its present value at settlement date and $1,224,140 is recorded in accounts payable at March 31, 2014.
	On August 14, 2012, the Company entered into an agreement with a shareholder to buy back 500,000 shares of common stock for $100,000. The order also called upon the payment of $50,000 in legal fees. As of December 31, 2012, the Company had not received the 500,000 shares of common stock but had paid the settlement. The Company received these shares in February 2013.

Related_Party

Related Party	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	17. Related Party
	Otis Fund, a company controlled by a former consultant, who owns in excess of 5% of the Company’s outstanding shares, had a consulting agreement to provide marketing and sales services to HCCA. The contract was due to expire on January 2, 2017; however the Company terminated the agreement for cause in September 2013. The annual fees related to these services were $360,000. In connection with this agreement, the Company recorded $300,000 and $360,000 for the years ended December 31, 2013 and 2012, respectively.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	18. Subsequent Events
	On April 4, 2014, we entered into a Note Purchase Agreement (the “Purchase Agreement”) with the persons named therein (each a “Lender”, and, collectively, the “Lenders”) pursuant to which the Lenders loaned us $1,000,000 and we issued $1,000,000 in Secured Convertible Term Notes (the “Notes”) to the Lenders. Selway Capital Holdings LLC, which loaned us $900,000 as a Lender, is 50% owned by Edmundo Gonzalez and Yaron Eitan, each of whom is one of our directors. The Notes: (i) bear interest at the annual rate of eight percent (8%), (ii) will be payable as to principal and interest on demand on April 2, 2015 (the “Maturity Date”), subject to acceleration upon an event of default, and (iii) may be prepaid by the Company at any time prior to the maturity date.
	Pursuant to the Security Agreement dated April 4, 2014 (the “Security Agreement”), we granted the Lenders a first priority security interest to all of the and assets of 340 Basics. In addition, we granted the Lenders a second priority security interest in and to all our other assets, including equity interests in all other subsidiaries. Such second priority security interest is subordinate only to the security interest of Partners for Growth III, L.P., the Company’s senior lender.
	We covenanted and agreed that: (a) if, as of May 4, 2014, we had failed to secure at least $1,500,000 in a new financing (the “Next Financing Round”), such failure would constitute an event of default; (b) if, as of May 4, 2014, we had secured at least $1,500,000 in a new financing, but less than $3,500,000, then we would be entitled to an additional 30 days in which to secure an additional amount so that the aggregate amount raised totals $3,500,000; (c) if, on or before expiration of such second 30 day period, we had failed to secure at least $3,500,000, such failure will constitute an event of default.
	On May 2, 2014, we and the Lenders agreed to extend the time periods specified in the foregoing covenants by five days from the original maturity date to May 9th, 2014. On May 7, 2014, the Company and the Lenders agreed to further extend the time periods specified in the foregoing covenants from May 9, 2014 to May 23, 2014, which will allow the Company time to continue exploring its financing options.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements including disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable represent amounts owed to the Company for products sold and services rendered net of an allowance for doubtful accounts. The Company grants unsecured credit to its customers. The Company continuously monitors the payment performance of its customers to ensure collections and minimize losses. Management does not believe that significant credit risks exist. An allowance for doubtful accounts is based upon the credit profiles of specific customers, economic and industry trends and historic payment experience. There is no allowance for doubtful accounts at March 31, 2014 and December 31, 2013.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventories consist of finished pharmaceutical products and are recorded at the lower of cost or market, with the cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in values is first recognized.
Rebates Policy [Policy Text Block]	'
	Rebates
	Pharmaceutical manufacturers offer rebates for selected brand drugs. The Company currently receives these rebates through a third party administrator. The rebates are considered earned when members (employees of customers) order the drugs. Rebates earned are paid to the Company by the third party administrator quarterly. Rebates earned are recognized as a reduction to cost of revenue. The portion of the rebate payable to customers is simultaneously recognized as a reduction of revenue. Management evaluates rebates receivable at the end of every reporting period and adjusts the amount reflected on the accompanying balance sheet to net realizable value. An adjustment is also made to the rebate payable to customers to correspond with any adjustment that applies to rebates receivable.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost less accumulated amortization and depreciation. Leasehold improvements are amortized using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the assets. Furniture and fixtures are depreciated using the straight-line method over the estimated useful lives of the assets of 5 years. Computer equipment and software are depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 5 years.
Development Stage Company Policy [Policy Text Block]	'
	Internal-Use Software Development Costs
	The Company capitalizes certain costs associated with the purchase and/or development of internal-use software, including its website. Generally, external and internal costs incurred during the application development stage of a project are capitalized. The application development stage of a project generally includes software design and configuration, coding, testing and installation activities. Training and maintenance costs are expensed as incurred. Upgrades and enhancements are capitalized if it is probable that such expenditures will result in additional functionality. Capitalized software costs are amortized using the straight-line method over the estimated useful life of the assets, which approximates 3 years.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Long-Lived Assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the fair value of the asset as compared to its carrying value. During the three months ended March 31, 2014 and March 31, 2013, the Company did not record any impairment charges.
Investment, Policy [Policy Text Block]	'
	Investments Held in Trust
	The Company applies the provisions of ASC Topic 320-10, Investment - Debt and Equity, to account for investments held in trust, which comprise only of held-to maturity securities. Held-to-maturity securities are those securities, which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost on the accompanying balance sheets and adjusted for any amortization or accretion of premiums or discounts.
Deferred Charges, Policy [Policy Text Block]	'
	Deferred Financing Costs
	Costs related to obtaining long-term debt financing have been capitalized and amortized over the term of the related debt using the straight line method. Amortization of deferred financing costs charged to interest expense was $31,061 and $400,704 for the three months ended March 31, 2014 and 2013, respectively. The unamortized balance was $246,086 and $254,252 at March 31, 2014 and December 31, 2013, respectively.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments
	The Company applies the provisions of ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC Topic 815-40”), under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, such warrants are recorded as a liability and are revalued at fair value at the end of each reporting period. Furthermore, under derivative accounting, the warrants are initially recorded at their fair value. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as a change in fair value in the statement of operations on the issuance date.
Debt, Policy [Policy Text Block]	'
	Debt Discounts
	Debt discounts are amortized using the effective interest rate method over the term of the related debt. The result achieved using the straight-line method is not materially different than those which would result using the effective interest method.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Payments
	Share-based payments to employees are measured at the fair value of the award on the date of grant based on the estimated number of awards that are ultimately expected to vest. The compensation expense resulting from such awards is recorded over the vesting period of the award in selling, general and administrative expenses on the accompanying consolidated statements of operations.
	Share-based payments to non-employees for services rendered are recorded at either the fair value of the services rendered, or the fair value of the awards, whichever is more readily determinable. The expense resulting from such awards is marked to market over the vesting period of the award in selling, general and administration expenses on the accompanying consolidated statements of operations.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company typically enters into annual renewable agreements with its customers to provide pharmacy benefit management on a fixed price or self-insured basis. The Company records revenues from all its current contracts with customers gross as the Company acts as principal based on the following factors: 1) the Company has a separate contractual relationship with its customers and with its claims adjudicator to whom the Company pays the costs of the prescription drugs consumed by its customers (the claims), 2) the Company through its claim adjudicator is responsible to validate and manage the claims, and 3) the Company bears the credit risk for the amount due from the customers. Revenues are recorded monthly as earned. The Company also operates a mail order pharmacy that services plan members. All revenues and associated costs from dispensing drugs by the mail order pharmacy to our plan members, excluding the members’ co-pay are eliminated as inter-company revenues. Some of the contracts contain terms whereby the Company makes certain financial guarantees regarding prescription costs. Actual performance is compared to the guaranteed measure throughout the period and accruals are recorded as an offset to revenue if the Company fails to meet a financial guarantee.
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Sales
	Cost of sales includes claim payments for both fixed- price and self-insured programs, administrative fees paid for processing the claims to the claims adjudicator and, the cost of prescription drugs of the mail order pharmacy.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising Expenses
	Advertising expenses are expensed as incurred and included in selling, general and administrative expenses on the accompanying statements of operations. Advertising expenses were approximately $0 and $24,624 for the three months ended March 31, 2014 and 2013, respectively.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established when realization of net deferred tax assets is not considered more likely than not.
	Uncertain income tax positions are determined based upon the likelihood of the positions being sustained upon examination by taxing authorities. The benefit of a tax position is recognized in the consolidated financial statements in the period during which management believes it is more likely than not that the position will not be sustained. Income tax positions taken are not offset or aggregated with other positions. Income tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of income tax benefit that is more than 50 percent likely of being realized if challenged by the applicable taxing authority. The portion of the benefits associated with income tax positions taken that exceeds the amount measured is reflected as income taxes payable.
	The Company recognizes interest related to uncertain tax positions in interest expense. The Company recognizes penalties related to uncertain tax positions in income tax expense.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements
	The Company applies recurring fair value measurements to its derivative instruments in accordance with ASC 820, Fair Value Measurements. In determining fair value, the Company uses a market approach and incorporates assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation techniques. These inputs can be readily observable, market corroborated or generally unobservable internally-developed inputs. Based upon the observability of the inputs used in these valuation techniques, the Company’s derivative instruments are classified as follows:
	Level 1:	The fair value of derivative instruments classified as Level 1 is determined by unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
	Level 2:	The fair value of derivative instruments classified as Level 2 is determined by quoted market prices for similar assets or liabilities in active markets, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
	Level 3:	The fair value of derivative instruments classified as Level 3 is determined by internally-developed models and methodologies utilizing significant inputs that are generally less readily observable from objective sources.
	At March 31, 2014 and December 31, 2013 the Company had 2,000,000 warrants exercisable into its shares of common stock that were issued in connection with Selway’s initial public offering (“Selway IPO Warrants”). These warrants are publicly traded and are classified as liabilities. Additionally, HCCA issued 296,250 warrants in connection with the Bridge Financing with identical terms as the Selway IPO Warrants. The Company has valued all of these warrants at March 31, 2014 and December 31, 2013 based on the closing price of the Selway IPO Warrants. Because the market for the Selway IPO Warrants is not active, the valuation is classified as a Level 2 measurement. These warrants are exercisable at $7.50 a share and expire on November 7, 2016.
	On December 31, 2013, the Company executed a forbearance agreement with the holders of its senior convertible debt. Among other things, this agreement required the Company to issue 425,000 shares of common stock to the senior convertible debt holders and permit the redemption of 25,000 shares at the rate of $10 per share through June 30, 2019 (the “Senior Debt Redemption Feature”). The Company evaluated the redemption terms embedded in the agreement and determined that such terms should be bifurcated from the common stock and recorded as a liability. The Company determined the fair value of the Senior Debt Redemption Feature utilizing a Black-Scholes valuation model. The key inputs to the valuation were the Company’s share price at the date of valuation and the expected volatility. The Company did not become publicly traded until April 11, 2013 and therefore determined its expected volatility from a selection of similar publicly traded companies. The valuation is classified as a Level 2 valuation based on the use of volatility calculations from other publicly traded companies.
	On December 31, 2013, the Company issued $2,325,125 of Junior Convertible Notes convertible into 1,550,083 shares of common stock maturing on December 31, 2015 and Warrants to acquire 1,550,083 shares of common stock at $1.50 that expire on December 31, 2018. The conversion feature in the Junior Convertible Notes and Warrant agreement contain anti-dilution provisions that cause the related conversion rate and exercise price to decrease and the related shares increase if the Company is deemed to issue equity at a per share value less than the then conversion rate and exercise price. The Company evaluated this feature and determined that conversion feature in the Junior Convertible Notes should be bifurcated from the underlying debt agreement and recorded as a liability and the Warrants to be classified as liabilities (the Junior Convertible Notes Conversion Feature and Warrants).
	The Company utilized a Monte Carlo simulation model to estimate the value of the Junior Convertible Notes Conversion Feature and Warrants. The Company classified this valuation as Level 3 valuation as the key inputs to the Monte Carlo include timing of equity raises and the estimated share price at such dates.
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of March 31, 2014:
			Level 1		Level 2		Level 3		Total
	Senior debt redemption feature		$	-	$	250,000	$	-	$	250,000
	Warrants and convertible feature junior convertible note		$	-	$		$	4,201,000	$	4,201,000
	Warrants		$	-	$	252,589	$	-	$	252,589
	Total derivative liabilities		$	-	$	502,589	$	4,201,000	$	4,703,589
	The table below presents the activity in the Company’s derivative instruments measured at fair value on a recurring basis for the three months ended March 31, 2014:
			Beginning of		Issuances		Changes in		Balance at
			Period				Fair Value		end of Period
	Warrants and convertible feature convertible notes		$	5,087,000	$	-	$	-886,000	$	4,201,000
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of December 31, 2013:
			Level 1		Level 2		Level 3		Total
	Senior debt redemption feature		$	-	$	250,000	$	-	$	250,000
	Warrants and convertible feature junior convertible note		$	-	$		$	5,087,000	$	5,087,000
	Warrants		$	-	$	68,889	$	-	$	68,889
	Total derivative liabilities		$	-	$	318,889	$	5,087,000	$	5,405,889
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The fair values of cash and cash equivalents, accounts receivable, rebates receivable and accounts payable approximate their carrying values due to the short-term nature of the instruments. The fair values of long-term debt approximates their carrying value due to the fact that these instruments were modified or executed at year-end. The fair value of investments held in trust is not materially different than its carrying value because of the short-term nature of the investments.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Risks and Concentrations
	The Company utilizes the services of a single claims adjudicator. If there is an adverse situation in this relationship, the Company’s mail order pharmaceutical fulfillment services would be ineffective until a replacement claims adjudicator was obtained.
	Approximately 25% of the Company’s revenues for the three months ended March 31, 2014 were derived from one customer. Revenues from this customer were 13% of the Company’s revenues for the year ended December 31, 2013. No amounts were due from this customer at March 31, 2014 or December 31, 2013. In addition, the customers of one of the Company’s resellers accounted for approximately 25% of the Company’s revenue for the three months ended March 31, 2014 and for the year ended December 31, 2013. Amounts due from these customers represented 63% and 76% of accounts receivable at March 31, 2014 and December 31, 2013, respectively.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all cash in bank, money market funds and certificates of deposit with an original maturity of less than three months to be cash equivalents. The Company maintains its cash and cash equivalents in one financial institution. Cash balances on hand at this financial institution may exceed the insurance coverage provided to the Company by the Federal Deposit Insurance Corporation at various times during the year.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings (Loss) Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share are determined in the same manner as basic earnings (loss) per share, except that the number of shares is increased to include potentially dilutive securities using the treasury stock method. Because the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share because the effect of including them is anti-dilutive.
			Three Months		Three Months
			Ended March		Ended March
			31, 2014		31, 2013
	Basic and Diluted:
	Net loss		$	-3,046,156	$	-3,648,613
	Weighted average shares			8,846,103		40,250,009
	Basic loss per common share		$	-0.34	$	-0.09
	The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
				Three Months		Three Months
				Ended March		Ended March
				31, 2014		31, 2013
	Dilutive Potential Common Shares
	Warrants			5,596,106		1,585,833
	Restricted stock awards			-		75,292
	Convertible notes payable			3,750,083		2,666,667

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	'
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of March 31, 2014:
		Level 1		Level 2		Level 3		Total
	Senior debt redemption feature	$	-	$	250,000	$	-	$	250,000
	Warrants and convertible feature junior convertible note	$	-	$		$	4,201,000	$	4,201,000
	Warrants	$	-	$	252,589	$	-	$	252,589
	Total derivative liabilities	$	-	$	502,589	$	4,201,000	$	4,703,589
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of December 31, 2013:
		Level 1		Level 2		Level 3		Total
	Senior debt redemption feature	$	-	$	250,000	$	-	$	250,000
	Warrants and convertible feature junior convertible note	$	-	$		$	5,087,000	$	5,087,000
	Warrants	$	-	$	68,889	$	-	$	68,889
	Total derivative liabilities	$	-	$	318,889	$	5,087,000	$	5,405,889
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The table below presents the activity in the Company’s derivative instruments measured at fair value on a recurring basis for the three months ended March 31, 2014:
		Beginning of		Issuances		Changes in		Balance at
		Period				Fair Value		end of Period
	Warrants and convertible feature convertible notes	$	5,087,000	$	-	$	-886,000	$	4,201,000
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months		Three Months
		Ended March		Ended March
		31, 2014		31, 2013
	Basic and Diluted:
	Net loss	$	-3,046,156	$	-3,648,613
	Weighted average shares		8,846,103		40,250,009
	Basic loss per common share	$	-0.34	$	-0.09
Diluted Loss Per Shares [Table Text Block]	'
	The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
			Three Months		Three Months
			Ended March		Ended March
			31, 2014		31, 2013
	Dilutive Potential Common Shares
	Warrants		5,596,106		1,585,833
	Restricted stock awards		-		75,292
	Convertible notes payable		3,750,083		2,666,667

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment is as follows:
		March 31,		December 31,
		2014		2013
	Furniture, fixtures and equipment	$	1,662,201	$	1,662,201
	Leasehold improvements		60,168		50,548
			1,722,369		1,712,749
	Accumulated depreciation and amortization		-650,510		-564,234
	Net property and equipment	$	1,071,859	$	1,148,515

Software_net_Tables

Software, net (Tables)	3 Months Ended
	Mar. 31, 2014
Capitalized Computer Software, Net [Abstract]	'
Schedule of Capitalized Computer Software, Net [Table Text Block]	'
	Software, net is as follows:
		March 31,		December 31,
		2014		2013
	Software costs	$	472,489	$	472,489
	Accumulated amortization		-97,496		-73,106
	Net software costs	$	374,993	$	399,383

Deferred_Financing_Costs_Table

Deferred Financing Costs (Tables)	3 Months Ended
	Mar. 31, 2014
Deferred Finance Costs [Abstract]	'
Schedule of Fresh-Start Adjustments [Table Text Block]	'
	Deferred financing costs are as follows:
	Balance January 1, 2014	$	254,252
	Costs incurred for forbearance, waiver and modification to the senior convertible note for the three months ended March 31, 2014		22,895
	Amortization for the three months ended March 31, 2014		-31,061
	Balance March 31, 2014	$	246,086

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses are as follows:
			March 31,		December 31,
			2014		2013
	Accrued severance costs*		$	271,154	$	750,000
	Accrued rebates			691,983		596,905
	Accrued registration rights penalties**			910,000		864,000
	Accrued professional fees			480,000		67,686
	Accrued commissions			723,332		225,125
	Accrued franchise tax			303,981		263,981
	Accrued payroll			285,022		327,357
	Accrued expenses other			230,540		199,363
			$	3,896,012	$	3,294,467
		*	Payable to a former executive of the Company.
		**	Estimated penalties relating to late registration of shares of common stock in connection with the bridge notes and senior convertible note.

LongTerm_Debt_Tables

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Long-term Debt and Capital Lease Obligations, Current [Abstract]	'
Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity [Table Text Block]	'
		March 31, 2014		December 31, 2013
	Shareholder notes	$	6,750,000	$	6,750,000
	Placement notes		500,000		500,000
	Management incentive notes		2,500,000		2,500,000
			9,750,000		9,750,000
	Less debt discount		-6,616,787		-6,815,703
		$	3,133,213	$	2,934,297
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Future maturities of the Incentive Notes based on the Company’s estimates which do not reflect any limitation of repayment that may exist due to the terms of other debt then outstanding are as follows:
	June 30,
	2014	$	-
	2015		-
	2016		399,000
	2017		1,789,000
	2018		3,622,000
	Thereafter		3,940,000
		$	9,750,000
Schedule of Capital Leased Assets [Table Text Block]	'
	The Company has entered into capital lease agreements for equipment, which expire at various dates through November 2019. The assets capitalized under these leases and associated accumulated depreciation at March 31, 2014 and December 31, 2013 are as follows:
		March 31,		December 31,
		2014		2013
	Furniture and equipment	$	1,050,343	$	1,050,343
	Accumulated depreciation		-431,014		-370,780
		$	619,329	$	679,563
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	Minimum future lease payments under capital lease obligations as of March 31, 2014 are as follows:
	Year Ended March 31,
	2015	$	264,006
	2016		240,390
	2017		169,297
	2018		137,316
	2019		35,747
	Thereafter		23,831
	Total future minimum lease payments		870,587
	Less amount representing interest		-125,616
	Present value of net minimum lease payments		744,971
	Less current portion		-209,267
		$	535,704

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum payments for non-cancelable operating leases are as follows as of March 31, 2014:
	Year ended March 31,
	2015	$	205,510
	2016		216,975
	2017		201,465
		$	623,950

Liquidity_and_Financial_Condit1

Liquidity and Financial Condition (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Liquidity and Financial Condition [Line Items]	'	'	'
Working Capital Deficit	$8,140,621	'	$5,100,047
Stockholders' Equity Attributable To Parent	-14,505,408	'	-11,855,641
Net Income (Loss) Attributable To Parent	-3,046,156	-3,648,613	24,544,708
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$1,501,968	'	$9,606,056

The_Merger_Details_Textual

The Merger (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Nov. 22, 2013	Jul. 17, 2013
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	400,000	'	'	'
Class Of Warrant Or Rights Issued	2,000,000	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	7.5	'	'	'	'	'
Proceeds from Issuance of Warrants	$0	$120,937	'	'	'	'
Interest Expense, Debt	592,000	'	'	713,196	'	'
Debt Instrument, Unamortized Discount	6,616,787	'	6,815,703	'	'	'
Debt Instrument Additional Interest Expense	1,182,327	'	'	'	'	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	'	$8
Conversion Of Stock To Underwriters	237,007	'	'	'	'	'
Transaction Cost Total	577,069	'	'	'	'	'
Aggregate Shares Of Common Stock For Placement Warrant	100,000	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	'	'	'	'	1,000,000	'
Percentage For Holders Issued And Outstanding Shares	75.00%	'	'	'	'	'
Percentage For Members Of Management	25.00%	'	'	'	'	'
Description For Warrants Exercisable	'common stock exceeds $12.00 per share for 20 trading days in any 30-trading-day period	'	'	'	'	'
Percentage For Consideration Received Owed To Adviser	5.00%	'	'	'	'	'
Percentage Common Stock And Incentive Stock	5.00%	'	'	'	'	'
Incentive Note Issued	500,000	'	'	'	'	'
Percentage Of Incentive Note Issued	5.00%	'	'	'	'	'
Description For Business Acquisition Transaction Factors	'The majority of shares of the Company post-closing were still owned by HCCA shareholders, who represented 60% of the Companys shares outstanding immediately after closing, if all shares subject to conversion in our post-closing tender offer actually convert to Series C (non-redeemable) common shares, and 65% of the Companys shares outstanding if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer. Estimates of HCCAs ownership do not include shares underlying warrants held by public investors and the Companys sponsors restricted incentive shares held by management. However, HCCA shareholders would still have 51% of the Companys shares post-closing when including shares underlying warrants and restricted shares and assuming all redeemable shares convert to Series C shares, and 54% of the Companys shares post-closing if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer.	'	'	'	'	'
Business Acquisition Purchase Consideration Percentage	10.00%	'	'	'	'	'
Short-term Debt, Terms	'The agreement requires damages of 1% per month of the Bridge Financing, capped at 10%, for each month the Company does not comply with the requirement.	'	'	'	'	'
Subsequent Event [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument, Maturity Date	9-May-14	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'	'	'	'	'
Incentive Stock [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, Other	335,000	'	'	'	'	'
Series C Common Stock [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'	'	'	'	'
Promissory Note Convertible Into Common Stock	10,000	'	'	'	'	'
Conversion of Stock, Amount Converted	11,948,361	'	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	520,000	'	'	'	'	'
Stock Issued During Period, Value, Issued for Services	750,000	'	'	'	'	'
Series A Common Stock [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument, Annual Principal Payment	3,101,038	'	'	'	'	'
Debt Conversion, Converted Instrument, Rate	5.00%	'	'	'	'	'
Conversion of Stock, Shares Converted	878,481	'	'	'	'	'
Debt Instrument, Convertible, Conversion Price	$3.53	'	'	'	'	'
Bridge Financing [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument Additional Interest Expense	1,182,327	'	'	'	'	'
Debt Instrument, Annual Principal Payment	3,159,624	'	'	'	'	'
Repayments of Notes Payable	3,025,000	'	'	'	'	'
Bridge Financing [Member] | Series C Common Stock [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Promissory Note Convertible Into Common Stock	315,959	'	'	'	'	'
Debt Instrument, Periodic Payment, Principal	3,025,000	'	'	'	'	'
Debt Conversion, Converted Instrument, Rate	5.00%	'	'	'	'	'
Conversion of Stock, Shares Converted	281,554	'	'	'	'	'
Minimum [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Class Of Warrant Or Right Exercise Price Of Warrants Adjustment	'	'	$1.50	'	'	'
Maximum [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Class Of Warrant Or Right Exercise Price Of Warrants Adjustment	'	'	$7.50	'	'	'
Warrant [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument, Maturity Date	6-Nov-16	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,000,000	'	'	'	'	'
Financing Interest Expense	561,712	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	26,002	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$10	'	'	'	'	'
Criteria [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Class Of Warrant Or Right Exercise Price Of Warrants Adjustment	'	'	$7.50	'	'	'
Healthcare Corporation Of America [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,200,000	'	'	'	'	'
Business Acquisition, Notes Repayment Description	'The notes will be repaid from 18.5% of the Companys free cash-flow (as defined) in excess of $2,000,000.	'	'	'	'	'
Value Per Share	$15	'	'	'	'	'
Amortization of Debt Discount (Premium)	1,018,851	'	'	'	'	'
Interest Expense, Debt	1,732,047	'	'	'	'	'
Debt Instrument, Unamortized Discount	2,445,242	'	'	'	'	'
Healthcare Corporation Of America [Member] | Bridge Financing [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	7.5	'	'	'	'	'
Value Per Share	$59.25	'	'	'	'	'
Bridge Financing, Units Issued, Preferred Shares	10,000	'	'	'	'	'
Bridge Financing, Promissory Note Face Value	100,000	'	'	'	'	'
Preferred Stock Dividends, Income Statement Impact	3,532,858	'	'	'	'	'
Class Of Warrant Or Right Expired	7-Nov-16	'	'	'	'	'
Conversion of Stock, Shares Converted	592,500	'	'	'	'	'
Aggregate Shares Of Common Stock For Placement Warrant	5,000	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	296,250	'	'	'	'	'
Conversion Of Preferred Stock Shares Converted Percentage	3.70%	'	'	'	'	'
Healthcare Corporation Of America [Member] | Notes Payable, Other Payables [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Liabilities Assumed	1,977,570	'	'	'	'	'
Healthcare Corporation Of America [Member] | Promissory Note [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	750,000	'	'	'
Selway Capital Holdings [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	520,000	'	'	'	'	'
Proceeds from Issuance of Warrants	4,018,000	'	'	'	'	'
Selway Capital Holdings [Member] | Promissory Note [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Debt Instrument, Face Amount	750,000	'	'	'	'	'
Escrow [Member] | Healthcare Corporation Of America [Member] | Promissory Note [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition Cost Of Acquired Entity Purchase Prices	7,500,000	'	'	'	'	'
Earnout Payment Shares [Member] | Healthcare Corporation Of America [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,800,000	'	'	'	'	'
Earnout Payment Shares [Member] | Healthcare Corporation Of America [Member] | Criteria One [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1,400,000	'	'	'	'	'
Criteria For Payment Of Earn Out Payment Shares	'1,400,000 shares if the Company achieves consolidated gross revenue of $150,000,000 for the twelve months ended March 31, 2014 or June 30, 2014	'	'	'	'	'
Consolidated Gross Revenue	150,000,000	'	'	'	'	'
Earnout Payment Shares [Member] | Healthcare Corporation Of America [Member] | Criteria Two [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	1,400,000	'	'	'	'	'
Criteria For Payment Of Earn Out Payment Shares	'1,400,000 shares if the Company achieves consolidated gross revenue of $300,000,000 for the twelve months ended March 31, 2015 or June 30, 2015	'	'	'	'	'
Consolidated Gross Revenue	$300,000,000	'	'	'	'	'
Chardan Capital Markets Llc [Member] | Healthcare Corporation Of America [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	'	'	546,002	'	'	'
Management Incentive Shares [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,500,000	'	'	'	'	'
Management Incentive Shares [Member] | June 30, 2014 [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	400,000	'	'	'	'	'
Management Incentive Shares [Member] | June 30, 2015 [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	350,000	'	'	'	'	'
Management Incentive Shares [Member] | Rescission Agreements [Member]	'	'	'	'	'	'
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Cancelled	750,000	'	'	'	'	'

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Significant Accounting Policies [Line Items]	'	'
Senior debt redemption feature	$250,000	$250,000
Warrants and convertible feature junior convertible note	4,201,000	5,087,000
Warrants	252,589	68,889
Total derivative liabilities	4,703,589	5,405,889
Fair Value, Inputs, Level 1 [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Senior debt redemption feature	0	0
Warrants and convertible feature junior convertible note	0	0
Warrants	0	0
Total derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Senior debt redemption feature	250,000	250,000
Warrants	252,589	68,889
Total derivative liabilities	502,589	318,889
Fair Value, Inputs, Level 3 [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Senior debt redemption feature	0	0
Warrants and convertible feature junior convertible note	4,201,000	5,087,000
Warrants	0	0
Total derivative liabilities	$4,201,000	$5,087,000

Significant_Accounting_Policie4

Significant Accounting Policies (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Significant Accounting Policies [Line Items]	'
Warrants and convertible feature convertible notes, Beginning of Period	$5,087,000
Warrants and convertible feature convertible notes, Issuances	0
Warrants and convertible feature convertible notes, Changes in Fair Value	-886,000
Warrants and convertible feature convertible notes, Balance end of Period	$4,201,000

Significant_Accounting_Policie5

Significant Accounting Policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Basic and Diluted:	'	'
Net loss	($3,046,156)	($3,648,613)
Weighted average shares (in shares)	8,846,103	40,250,009
Basic loss per common share (in dollars per share)	($0.34)	($0.09)

Significant_Accounting_Policie6

Significant Accounting Policies (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Dilutive Potential Common Shares	'	'
Warrants	$5,596,106	$1,585,833
Restricted stock awards	0	75,292
Convertible notes payable	$3,750,083	$2,666,667

Significant_Accounting_Policie7

Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Jul. 17, 2013
Significant Accounting Policies [Line Items]	'	'	'	'
Amortization of Financing Costs	$31,061	$400,704	'	'
Postconfirmation, Deferred Financing Costs	246,086	'	254,252	'
Advertising Expense	0	24,624	'	'
Warrants Issued During Period	2,000,000	'	2,000,000	'
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	296,250	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	7.5	'	'	'
Warrants Expiration Date	7-Nov-16	'	'	'
Revenue Reseller Percentage	25.00%	'	25.00%	'
Accounts Receivable Percentage	63.00%	'	76.00%	'
Debt Instrument, Convertible, Conversion Price	'	'	'	$8
Customer One [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Revenue Customer Percentage	25.00%	'	13.00%	'
Senior Convertible Debt [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Number of Shares Permitted to Redemption	'	'	25,000	'
Redemption Price Per Share	'	'	$10	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	425,000	'
Junior Convertible Note [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	1,550,083	'
Debt Conversion, Converted Instrument, Amount	'	'	$2,325,125	'
Debt Conversion, Converted Instrument, Warrants or Options Issued	1,550,083	'	1,550,083	'
Debt Instrument, Convertible, Conversion Price	$1.50	'	$1.50	'
Debt Conversion, Converted Instrument, Expiration or Due Date	'	'	31-Dec-18	'
Furniture and Fixtures [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'	'
Computer Equipment And Software [Member] | Minimum [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'	'
Computer Equipment And Software [Member] | Maximum [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'	'
Software and Software Development Costs [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Furniture, fixtures and equipment	$1,662,201	$1,662,201
Leasehold improvements	60,168	50,548
Property, Plant and Equipment, Gross	1,722,369	1,712,749
Accumulated depreciation and amortization	-650,510	-564,234
Net property and equipment	$1,071,859	$1,148,515

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation, Depletion and Amortization, Nonproduction, Total	$88,276	$74,693

Software_net_Details

Software, net (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Capitalized Computer Software, Net [Line Items]	'	'
Software costs	$472,489	$472,489
Accumulated amortization	-97,496	-73,106
Net software costs	$374,993	$399,383

Software_net_Details_Textual

Software, net (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Capitalized Computer Software, Net [Line Items]	'	'
Amortization, Total	$24,390	$0

Investments_Held_in_Trust_Deta

Investments Held in Trust (Details Textual) (USD $)	0 Months Ended	1 Months Ended
	Apr. 10, 2013	Nov. 30, 2011	Mar. 31, 2014
Investments Held in Trust [Line Items]	'	'	'
Investments and Cash Held In Trust	'	$20,600,000	'
Temporary Equity, Shares Outstanding	1,160,035	'	'
Escrow Deposit Disbursements Related To Shares Redemption	11,948,000	'	'
Trust Account Balance	$8,652,000	'	$8,652,482
Temporary Equity Shares Outstanding Redeemable Shares	839,965	'	'
Treasury Bills Maturity Days	'180 days or less	'	'
Redemption Of Shares Percentage	'	100.00%	'

Deferred_Financing_Costs_Detai

Deferred Financing Costs (Details) (USD $)	0 Months Ended	3 Months Ended
	Apr. 11, 2013	Mar. 31, 2014
Deferred Financing Costs [Line Items]	'	'
Balance January 1, 2014	'	$254,252
Costs incurred for forbearance, waiver and modification to the senior convertible note for the three months ended March 31, 2014	538,637	22,895
Amortization for the three months ended March 31, 2014	'	-31,061
Balance March 31, 2014	'	$246,086

Accured_Expenses_Details

Accured Expenses (Details) (USD $)	Mar. 31, 2014		Dec. 31, 2013
Accrued Expenses [Line Items]	'		'
Accrued severance costs	$271,154	[1]	$750,000	[1]
Accrued rebates	691,983		596,905
Accrued registration rights penalties	910,000	[2]	864,000	[2]
Accrued professional fees	480,000		67,686
Accrued commissions	723,332		225,125
Accrued franchise tax	303,981		263,981
Accrued payroll	285,022		327,357
Accrued expenses other	230,540		199,363
Accrued Liabilities, Total	$3,896,012		$3,294,467
[1]	Payable to a former executive of the Company.
[2]	Estimated penalties relating to late registration of shares of common stock in connection with the bridge notes and senior convertible note.

Line_of_Credit_Details_Textual

Line of Credit (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Apr. 11, 2013	Mar. 31, 2014
Line of Credit Facility [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$5,000,000	'
Line of Credit Facility, Expiration Period	'3 years	'
Amortization of Other Deferred Charges	$538,637	$22,895

Junior_Convertible_Note_Detail

Junior Convertible Note (Details Textual) (USD $)	3 Months Ended	12 Months Ended			3 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2013	Jul. 17, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
					Junior Convertible Note [Member]	Junior Convertible Note [Member]	Junior Convertible Note [Member]
							Agent [Member]
Junior Convertible Note [Line Items]	'	'	'	'	'	'	'
Warrants Exercise Price Per Share	'	'	'	'	'	'	$3
Accrued Legal Costs	'	'	'	'	'	$250,000	'
Debt Instrument, Face Amount	'	'	'	'	'	2,112,500	212,625
Debt Instrument, Convertible, Conversion Price	'	'	'	$8	$1.50	$1.50	'
Debt Conversion, Converted Instrument, Warrants or Options Issued	'	'	'	'	1,550,083	1,550,083	141,750
Derivative Liability	'	'	'	'	5,087,000	'	'
Debt Instrument, Unamortized Discount	6,616,787	'	6,815,703	'	2,325,000	'	'
Interest Expense, Debt	592,000	713,196	'	'	2,762,000	'	'
Debt Issuance Cost	'	'	'	'	202,035	'	'
Accrual On Estimated Penalty	$46,000	'	$272,000	'	'	'	'
Investment Warrants, Exercise Price	'	'	'	'	$3	'	'

Senior_Convertible_Note_Detail

Senior Convertible Note (Details Textual) (USD $)	1 Months Ended	0 Months Ended	3 Months Ended		0 Months Ended		12 Months Ended		12 Months Ended
	Jul. 17, 2013	Apr. 11, 2013	Mar. 31, 2014	Dec. 31, 2013	Jan. 06, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
					New Note [Member]	New Note [Member]	PFG Modification Agreement [Member]	PFG Before Modification Agreement [Member]	PFG After Modification Agreement [Member]	PFG Warrants [Member]
Senior Convertible Note [Line Items]	'	'	'	'	'	'	'	'	'	'
Convertible Secured Loans Amount	$5,000,000	'	'	'	'	'	'	'	'	'
Convertible Secured Loans Maturity	17-Jul-18	'	'	'	'	'	'	'	'	'
Interest Payable Description	5.25%	'	'	'	'	'	'	'	'	'
Debt Instrument, Convertible, Conversion Price	$8	'	'	'	'	'	'	'	'	'
Principal Repayment Percentage In Year One	60.00%	'	'	'	'	'	'	'	'	'
Principal Repayment Percentage In Year Two	40.00%	'	'	'	'	'	'	'	'	'
Rights Or Warrants Issued For Series C Common Stock Shares Issue	220,000	'	'	'	'	'	'	'	'	'
Rights Or Warrants Issued For Series C Common Stock Shares Issue Price Per Share	$7.50	'	'	'	'	'	'	'	'	'
Equity Warrants Amount	'	'	'	'	'	'	'	'	'	1,154,144
Discount On Loan	'	'	'	'	'	'	'	'	'	1,808,289
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	'	'	'	'	'	'	'	'	'	654,144
Notes Payable, Fair Value Disclosure	'	'	'	'	'	'	'	'	'	3,191,711
Payments of Loan Costs	'	'	'	'	'	'	'	'	'	328,712
Accrual On Estimated Penalty	'	'	46,000	272,000	'	'	'	'	'	'
Line Of Credit Facility Additional Borrowings	'	'	'	'	500,000	'	'	'	'	'
Debt Instrument Convertible Original Conversion Price 1	'	'	'	'	'	'	$2.50	'	'	'
Debt Instrument Convertible Original Conversion Price 1 Modified	'	'	'	'	'	'	$7.50	'	'	'
Pre Stock And Warrants Issued During Period Value Preferred Stock And Warrants Exercise	'	'	'	'	'	'	220,000	'	'	'
Post Stock And Warrants Issued During Period Value Preferred Stock And Warrants Exercise	'	'	'	'	'	'	555,000	'	'	'
Pre Warrants Exercise Price	'	'	'	'	'	'	$3	'	'	'
Post Warrants Exercise Price	'	'	'	'	'	'	$8	'	'	'
Common Stock, Shares, Issued	'	'	8,907,492	8,832,492	'	'	425,000	'	'	'
Option To Purchase Maximum Number Of Shares	'	'	'	'	'	'	25,000	'	'	'
Common Stock Purchase Price	'	'	'	250,000	'	'	'	'	'	'
Debt Instrument, Fee Amount	'	'	'	'	'	'	150,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	'	'	'	625,000	2,200,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	'	'	'	'	'	'	'	$8	$2.50	'
Amortization of Other Deferred Charges	'	538,637	22,895	'	'	'	298,129	'	'	'
Gains (Losses) on Extinguishment of Debt, Total	'	'	'	'	'	'	1,642,529	'	3,703,224	'
Debt Instrument, Fair Value Disclosure	'	'	'	'	'	1,296,776	'	'	'	'
Warrants and Rights Outstanding	'	'	'	'	'	'	'	'	2,866,566	'
Stock Issued During Period, Value, New Issues	'	'	'	'	'	'	'	'	637,500	'
Accrued Liabilities, Current	'	'	3,896,012	3,294,467	'	'	'	'	150,000	'
Stock Issued During Period Value Redemption Feature	'	'	'	'	'	'	'	'	$250,000	'

Bridge_Notes_Details_Textual

Bridge Notes (Details Textual) (USD $)	3 Months Ended			1 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Sep. 12, 2012	Sep. 12, 2012	Sep. 30, 2012	Sep. 30, 2012	Sep. 12, 2012
			Series C Common Stock [Member]	Bridge Financing [Member]	Bridge Financing [Member]	Healthcare Corporation Of America [Member]	Healthcare Corporation Of America [Member]
					Series C Common Stock [Member]	Series C Common Stock [Member]	Bridge Financing [Member]
Disclosure Of Bridge Notes [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Conversion Of Redeemable Preferred Stock And Warrants	'	'	'	'	'	592,500	'
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	$296,250	'	'	'	'	$296,250	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	'	'	'	3,159,592	'	'
Stock Issued During Period, Shares, Conversion of Convertible Securities	'	'	'	'	315,959	'	'
Bridge Financing, Units Issued	'	'	'	'	'	'	59.25
Bridge Financing, Units Issued, Preferred Shares	'	'	'	'	'	'	10,000
Bridge Financing, Promissory Note Face Value	'	'	'	'	'	'	100,000
Fair Value Of Warrant Liability	'	'	'	82,726	'	'	'
Preferred Stock, Value, Issued	'	'	'	2,362,517	'	'	'
Notes Payable, Fair Value Disclosure	'	'	'	3,479,757	'	'	'
Debt Instrument, Unamortized Discount	6,616,787	6,815,703	'	2,445,242	'	'	'
Loan Processing Fee	'	'	'	673,229	'	'	'
Bridge Financing Units Issued Warrants	'	'	'	'	'	'	5,000
Debt Instrument, Annual Principal Payment	'	'	$3,025,000	'	'	'	'

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	$9,750,000	$9,750,000
Less debt discount	-6,616,787	-6,815,703
Other Long-term Debt, Noncurrent	3,133,213	2,934,297
Shareholder notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	6,750,000	6,750,000
Placement notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	500,000	500,000
Management incentive notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	$2,500,000	$2,500,000

LongTerm_Debt_Details_1

Long-Term Debt (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Capitalization, Long-term Debt [Line Items]	'	'
2014	$0	'
2015	0	'
2016	399,000	'
2017	1,789,000	'
2018	3,622,000	'
Thereafter	3,940,000	'
Long-term debt	$9,750,000	$9,750,000

LongTerm_Debt_Details_2

Long-Term Debt (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Capital Leased Assets [Line Items]	'	'
Furniture and equipment	$1,050,343	$1,050,343
Accumulated depreciation	-431,014	-370,780
Capital Leased Assets, Gross	$619,329	$679,563

LongTerm_Debt_Details_3

Long-Term Debt (Details 3) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Capital Leased Assets [Line Items]	'	'
2015	$264,006	'
2016	240,390	'
2017	169,297	'
2018	137,316	'
2019	35,747	'
Thereafter	23,831	'
Total future minimum lease payments	870,587	'
Less amount representing interest	-125,616	'
Present value of net minimum lease payments	744,971	'
Less current portion	-209,267	-216,400
Capital Lease Obligations	$535,704	'

LongTerm_Debt_Details_Textual

Long-Term Debt (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Debt Instrument, Interest Rate, Effective Percentage	25.00%	'
Debt Instrument, Convertible, If-converted Value in Excess of Principal	$2,000,000	'
Lease Expiration Date	30-Nov-19	'
Long-term Debt	9,750,000	9,750,000
Long-term Debt, Gross	500,000	'
Management Incentive Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Management Fees, Incentive Revenue	222,477	'
Payment for Management Fee	395,514	'
Long-term Debt	2,500,000	2,500,000
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Cancelled	'	750,000
Series C Common Stock [Member]	'	'
Debt Instrument [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	5,200,000	'
Stock Issued During Period, Value, New Issues	7,500,000	'
Senior Debt Obligations [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	$10,500,000	'

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Mar. 31, 2014

Aug. 15, 2013

Feb. 28, 2013

Dec. 31, 2012

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Aug. 15, 2013

Mar. 31, 2014

Selling, General and Administrative Expenses [Member]

Common Stock [Member]

Escrow Deposit Disbursements Related To Shares Redemption

Escrow Deposit Disbursements Related To Shares Redemption

Maximum [Member]

Minimum [Member]

Series B Common Stock [Member]

Series C Common Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

30,000,000

30,000,000

'

'

'

'

'

50,000,000

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

$0.00

$0.00

'

'

'

'

'

'

'

$0.31

$0.01

'

'

Common Stock, Shares, Outstanding

8,832,492

8,907,492

'

'

'

'

'

'

'

'

'

839,965

8,907,492

Conversion of Stock, Description

'

'

'

'

'

'

'

'Upon the merger, every 7.6923 HCCA shares of common stock were exchanged into 1 share of the Company’s common stock.

'

'

'

'

'

Common Stock, Shares, Issued

8,832,492

8,907,492

'

'

'

'

'

'

2,120,200

'

'

'

'

Stock Repurchase Program, Number of Shares Authorized to be Repurchased

'

'

'

'

500,000

'

'

'

'

'

'

'

'

Common Stock Redemption Amount

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

Equity Issued in Business Combination, Fair Value Disclosure

'

'

'

480,000

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross

750,000

'

'

'

'

'

'

'

'

'

'

'

'

Share Price

$7.30

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

400,000

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

'

'

'

'

'

'

'

2,920,000

'

'

'

'

'

Stock Redeemed From Trust Account

'

'

839,965

'

'

'

'

'

'

'

'

'

'

Stock Repurchased During Period, Shares

546,002

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options

851,667

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for settlement of disputes

'

'

'

'

'

'

75,000

'

'

'

'

'

'

Gain On Settlement OF Company Initial Estimate

'

'

'

'

'

$340,000

'

'

'

'

'

'

'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2014
Loss Contingencies [Line Items]	'
2015	$205,510
2016	216,975
2017	201,465
Total	$623,950

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended	12 Months Ended		0 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Aug. 14, 2012	Aug. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Aug. 14, 2012	Mar. 31, 2014
			Litigation [Member]	Litigation [Member]	Litigation [Member]	Litigation [Member]	Litigation [Member]	Employment Agreements [Member]
							Common Stock [Member]
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'
Salaries, Wages and Officers Compensation, Total	'	'	'	'	'	'	'	$1,700,000
Employee Service Share-Based Compensation Issued Stock Option	1,900,000	'	'	'	'	'	'	'
Loss Contingency, Damages Paid, Value	'	'	'	'	5,000,000	'	'	'
Litigation Settlement, Amount	'	'	'	2,700,000	'	'	'	'
Loss Contingency, Settlement Agreement, Terms	'	'	'	'15 months	'	'	'	'
Stock Issued During Period, Shares, Other	'	'	'	'	'	'	500,000	'
Stock Issued During Period, Value, Other	'	'	'	'	'	'	100,000	'
Legal Fees	'	'	50,000	'	'	'	'	'
Settlement Of Common Stock But Not Received	'	'	'	'	500,000	'	'	'
Payments for Rent	48,346	48,234	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	'	'	'	650,000
Accounts Payable	'	'	'	'	'	$1,224,140	'	'

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014
Related Party Transaction [Line Items]	'	'	'
Annual fees for Services	'	'	$360,000
Consulting Agreement Contract Expires	'	'	2-Jan-17
Professional Fees	$300,000	$360,000	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Line Items]	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Maturity Date	9-May-14
Noncontrolling Interest, Description	'(i) bear interest at the annual rate of eight percent (8%), (ii) will be payable as to principal and interest on demand on April 2, 2015 (the “Maturity Date”), subject to acceleration upon an event of default, and (iii) may be prepaid by the Company at any time prior to the maturity date.
Debt Instrument, Covenant Description	'(a) if, as of May 4, 2014, we had failed to secure at least $1,500,000 in a new financing (the “Next Financing Round”), such failure would constitute an event of default; (b) if, as of May 4, 2014, we had secured at least $1,500,000 in a new financing, but less than $3,500,000, then we would be entitled to an additional 30 days in which to secure an additional amount so that the aggregate amount raised totals $3,500,000; (c) if, on or before expiration of such second 30 day period, we had failed to secure at least $3,500,000, such failure will constitute an event of default.
Edmundo Gonzalez and Yaron Eitan [Member]	'
Subsequent Event [Line Items]	'
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	50.00%
Noncontrolling Interest, Preferred Stock Amount	900,000
Convertible Notes Payable [Member]	'
Subsequent Event [Line Items]	'
Debt Instrument, Face Amount	1,000,000